#$%^&*AU2018201532A120180322.pdf#####I: sxd Interwoven NRPortbl DCC SXD 6561220 _docx-2 03/2018 ABSTRACT A cancer chemotherapeutic agent that is particularly kinase suppressing and/or any other signaling pathway interfering agents and pharmaceutical formulations/compositions involving 5 the same and its process of manufacture is provided. A potential the cancer chemotherapeutic agent is provided which apart from stated anticancer activity as a proven kinase suppressing and/or any other signaling pathway interfering agent could also involve specific potential binding affinity towards the intramolecular G-Quadruplex DNA structure and/or other potential quadruplex forming sequences over duplex DNA structures favours 10 further diverse end use and application including but not limited to antiaging, antiangiogenic, antiproliferative, antitumor, antibiotic, antiviral, antifungal and multiple anticancer therapeutics, and also possesses favourable cytotoxicity values towards uncontrollably proliferative cells by inducing apoptosis irrespective of cells' p53 status, without being cytotoxic to normal cells.WO 2014/049619 PCT/IN 2013/000593 (2/15) Figure 2
